8-K: Assure Holdings Corp. to Sell Assets to National Neuromonitoring Services in $2.5 Million Deal

Assure Holdings Corp. has entered into an agreement to sell certain assets of its neuromonitoring business to National Neuromonitoring Services for $2.5 million, plus a potential earnout.

Summary

• Assure Holdings Corp. and its subsidiaries have agreed to sell certain assets to National Neuromonitoring Services, LLC for an initial payment of $2.5 million.
• The deal includes an earnout provision that could add up to $2 million more based on case volume within the first year after closing.
• The assets being sold include inventory, tangible personal property, contracts, permits, intellectual property, and data related to surgical cases.
• Excluded assets include accounts receivable, cash, certain contracts, employee benefit plans, and tax-related items.
• The purchaser will assume certain liabilities, including those related to transferred contracts and employees, as well as some taxes.
• The sellers will retain liabilities for indebtedness, certain taxes, litigation, employee-related issues, and other specific obligations.
• The first closing is expected no later than March 22, 2024, with a second closing to follow.
• The second closing is contingent upon the closing of Assure's merger transaction with Danam Health, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The deal provides Assure with immediate cash and potential future earnings, but also involves the sale of assets and the assumption of certain liabilities. The dependence on the Danam merger for the second closing introduces some uncertainty.

Positives

• The asset sale provides Assure Holdings with an immediate cash infusion of $2.5 million.
• The potential earnout of up to $2 million offers additional financial upside based on the performance of the acquired business.
• The deal allows Assure to divest certain assets and liabilities, potentially streamlining its operations.
• The purchaser assumes responsibility for certain liabilities, reducing Assure's financial obligations.

Negatives

• Assure is selling off key assets, which may impact its future revenue streams.
• The earnout is contingent on achieving specific case volume targets, which may not be met.
• The second closing is dependent on the merger with Danam Health, Inc., introducing uncertainty.
• The sellers retain significant liabilities, including those related to taxes and litigation.

Risks

• The earnout payment is not guaranteed and depends on achieving specific case volume targets.
• The second closing is contingent on the merger with Danam Health, Inc., which may not be completed.
• The sellers retain liabilities for taxes, litigation, and employee-related issues, which could lead to future financial obligations.
• There is a risk of disputes over the calculation of the earnout payment.
• The sale of assets could impact Assure's future revenue and growth potential.

Future Outlook

The document outlines the terms of the asset sale and the conditions for closing, including the earnout structure and indemnification clauses. The second closing is contingent on the merger with Danam Health, Inc. The document also includes forward-looking statements regarding the potential benefits and risks of the proposed transactions.

Industry Context

This asset sale reflects a strategic move by Assure Holdings to potentially streamline its operations and focus on other areas. The neuromonitoring industry is competitive, and this transaction could indicate a shift in Assure's business strategy. The sale to National Neuromonitoring Services suggests consolidation within the industry.

Comparison to Industry Standards

• The structure of the deal, with an upfront payment and an earnout based on performance, is a common practice in acquisitions within the healthcare services sector.
• The indemnification cap of $750,000 is typical for deals of this size, providing a level of protection for both parties.
• The inclusion of a non-compete agreement is standard in asset sales to protect the purchaser's investment.
• The reliance on case volume for the earnout is a common metric in healthcare transactions, reflecting the direct impact of service delivery on revenue.
• Comparable companies in the neuromonitoring space include NuVasive and Medtronic, which have also engaged in acquisitions and divestitures to optimize their portfolios.

Stakeholder Impact

• Shareholders may see a positive impact from the cash infusion and potential earnout.
• Employees may experience changes in employment status as some are offered positions with the purchaser.
• Customers may experience a transition in service providers.
• Suppliers may see a change in their business relationship with the purchaser.

Next Steps

• Complete the first closing by March 22, 2024.
• Achieve the case volume targets to trigger the earnout payments.
• Complete the merger with Danam Health, Inc. to enable the second closing.
• Transfer the assets and liabilities as outlined in the agreement.
• Ensure compliance with all terms and conditions of the agreement.

Key Dates

Keywords

asset sale, neuromonitoring, acquisition, earnout, merger, healthcare, indemnification, case volume, liabilities, contracts